Nascent Biotech, Inc.
NBIO · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $28 | $7 | $6 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $28 | $7 | $6 | $5 |
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | – | -100% | 33.3% | – |
| Gross Profit | -$0 | $0 | $1 | $1 |
| % Margin | – | – | 100% | 100% |
| EBITDA | $1 | -$1 | $0 | -$1 |
| % Margin | – | – | 1.7% | -80.4% |
| Net Income | -$2 | -$3 | -$0 | -$1 |
| % Margin | – | – | -47% | -127.9% |
| EPS Diluted | -0.013 | -0.024 | -0.004 | -0.013 |
| % Growth | 43.2% | -436.4% | 66.9% | – |
| Operating Cash Flow | -$1 | -$2 | $0 | -$1 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$2 | $0 | -$1 |